CCA
KYNB

Catalyst Capital Advisors’s Kyntra Bio KYNB Stock Holding History

Catalyst Capital Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6
Closed -$9K – 439
2018
Q3 		$9K Buy
6
+2
+50% +$3.08K ﹤0.01% 339
2018
Q2 		$6K Buy
+4
New +$5.21K ﹤0.01% 420

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Catalyst Capital Advisors's KYNB Position: Q4 2018 in Review

Catalyst Capital Advisors sold out of Kyntra Bio (KYNB) in Q4 2018, closing a stake of 6 shares — an estimated $9K sold.

Catalyst Capital Advisors first reported a position in KYNB in Q2 2018 and held it in 2 quarters. The position peaked at $9K in Q3 2018. 201 funds tracked by Wall St. Rank hold KYNB as of Q4 2018.

  • Catalyst Capital Advisors reported no remaining Kyntra Bio position as of Q4 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 6 Kyntra Bio shares in Q4 2018, an estimated $9K.
  • Catalyst Capital Advisors first reported a position in Kyntra Bio in Q2 2018 and held it in 2 quarters.
  • Catalyst Capital Advisors's Kyntra Bio position peaked at $9K in Q3 2018.
  • 201 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2018.

Based on Catalyst Capital Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.